Pregled bibliografske jedinice broj: 825532
Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?
Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity? // Croatian medical journal, 57 (2016), 3; 239-246 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 825532 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?
Autori
Duraković, Nadira ; Krečak, Ivan ; Perić, Zinaida ; Milošević, Milan ; Desnica, Lana ; Pulanić, Dražen ; Pusic, Iskra ; Kušec, Vesna ; Vrhovac, Radovan ; Pavletic, Steven Z ; Nemet, Damir
Izvornik
Croatian medical journal (0353-9504) 57
(2016), 3;
239-246
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
chronic graft-vs-host disease ; activity ; severity ; glycoprotein YKL-40
Sažetak
AIM: To investigate whether increased YKL-40 levels positively correlate with graft-vs-host disease (cGVHD) activity and severity and if YKL-40 could serve as a disease biomarker. METHODS: This case-control study was conducted at the University Hospital Centre Zagreb from July 2013 to October 2015. 56 patients treated with hematopoietic stem cell transplantation (HSCT) were included: 35 patients with cGVHD and 21 without cGVHD. There was no difference between groups in age, sex, median time from transplant to study enrollment, intensity of conditioning, type of donor, or source of stem cells. Blood samples were collected at study enrollment and YKL-40 levels were measured with ELISA. Disease activity was estimated using Clinician's Impression of Activity and Intensity of Immunosuppression scales and disease severity using Global National Institutes of Health (NIH) score. RESULTS: YKL- 40 levels were significantly higher in cGVHD patients than in controls (P=0.003). The difference remained significant when patients with myelofibrosis were excluded from the analysis (P=0.017). YKL-40 level significantly positively correlated with disease severity (P<0.001 ; correlation coefficient 0.455), and activity estimated using Clinician's Impression of Activity (P=0.016 ; correlation coefficient 0.412) but not using Intensity of Immunosuppression (P=0.085 ; correlation coefficient 0.296). CONCLUSION: YKL-40 could be considered a biomarker of cGVHD severity and activity. However, validation in a larger group of patients is warranted, as well as longitudinal testing of YKL-40 levels in patients at risk of developing cGVHD.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Sveučilište Libertas
Profili:
Lana Grković
(autor)
Steven Živko Pavletić
(autor)
Milan Milošević
(autor)
Vesna Kušec
(autor)
Dražen Pulanić
(autor)
Zinaida Perić
(autor)
Damir Nemet
(autor)
Nadira Duraković
(autor)
IVAN KREČAK
(autor)
Radovan Vrhovac
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE